Clinical Trial Update: Ruxolitinib Prior to Transplant in Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ruxolitinib before transplant in myelofibrosis was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: John Mascarenhas | Conditions: Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis | Phase 2 | Status: TERMINATED | Results posted: 2019-03-20